An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 6, 2014, Pages 666-674

  Langbaum, Jessica B ^a,b   Hendrix, Suzanne B ^c   Ayutyanont, Napatkamon ^a,b   Chen, Kewei ^a,b,d   Fleisher, Adam S ^a,b   Shah, Raj C ^e,f   Barnes, Lisa L ^e,f   Bennett, David A ^e,f   Tariot, Pierre N ^a,b,g   Reiman, Eric M ^a,b,g,h  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

^b ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^c Pentara Corporation   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^h TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Cognition; Composite endpoints; Power; Preclinical Alzheimer's disease; Prevention; Sample size

Indexed keywords

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CLINICAL EVALUATION; COGNITION ASSESSMENT; COMPOSITE COGNITIVE TEST SCORE; CONTROLLED STUDY; DEMENTIA ASSESSMENT; EPISODIC MEMORY; FEMALE; HUMAN; LOGIC; LOGICAL MEMORY DELAYED RECALL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY ASSESSMENT; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RECALL; SCORING SYSTEM; WORKING MEMORY; COGNITION DISORDERS; COHORT ANALYSIS; COMPLICATION; DISEASE COURSE; PSYCHOLOGICAL RATING SCALE; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 84927175617     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.02.002     Document Type: Article

References (55)

1. Alzheimer's Association 2013 Alzheimer's disease facts and figures Alzheimers Dement 9 2013 208 245
2. R. Brookmeyer, S. Gray, and C. Kawas Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am J Public Health 88 1998 1337 1342
3. E.M. Reiman, J.B. Langbaum, and P.N. Tariot Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible Biomark Med 4 2010 3 14
4. E.M. Reiman, J.B. Langbaum, A.S. Fleisher, R.J. Caselli, K. Chen, and N. Ayutyanont Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments J Alzheimers Dis 25 Suppl 3 2011 293 301
5. S.M. Mills, J. Mallmann, A.M. Santacruz, A. Fuqua, M. Carril, and P.S. Aisen Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial Rev Neurol (Paris) 169 2013 737 743
6. R. Sperling, M. Donohue, and P. Aisen The A4 trial: anti-amyloid treatment of asymptomatic Alzheimer's disease Alzheimers Dement 8 2012 425 426
7. A.D. Roses, M.W. Lutz, H. Amrine-Madsen, A.M. Saunders, D.G. Crenshaw, and S.S. Sundseth A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease Pharmacogenomics J 10 2010 375 384
8. J.B. Langbaum, A.S. Fleisher, K. Chen, N. Ayutyanont, F. Lopera, and Y.T. Quiroz Ushering in the study and treatment of preclinical Alzheimer disease Nat Rev Neurol 9 2013 371 381
9. ADAPT Research Group Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Archives of Neurology 65 2008 896 905
10. S.T. DeKosky, J.D. Williamson, A.L. Fitzpatrick, R.A. Kronmal, D.G. Ives, and J.A. Saxton Ginkgo biloba for prevention of dementia: a randomized controlled trial JAMA 300 2008 2253 2262
11. N.B. Silverberg, L.M. Ryan, M.C. Carrillo, R. Sperling, R.C. Petersen, and H.B. Posner Assessment of cognition in early dementia Alzheimers Dement 7 2011 e60 e76
12. S.J. Cano, H.B. Posner, M.L. Moline, S.W. Hurt, J. Swartz, and T. Hsu The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts J Neurol Neurosurg Psychiatry 81 2010 1363 1368
13. P.S. Aisen, S. Andrieu, C. Sampaio, M. Carrillo, Z.S. Khachaturian, and B. Dubois Report of the task force on designing clinical trials in early (predementia) AD Neurology 76 2011 280 286
14. M.F. Elias, A. Beiser, P.A. Wolf, R. Au, R.F. White, and R.B. D'Agostino The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort Arch Neurol 57 2000 808 813
15. J. Saxton, O.L. Lopez, G. Ratcliff, C. Dulberg, L.P. Fried, and M.C. Carlson Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset Neurology 63 2004 2341 2347
16. D.K. Johnson, M. Storandt, J.C. Morris, and J.E. Galvin Longitudinal study of the transition from healthy aging to Alzheimer disease Archives of Neurology 66 2009 1254 1259
17. R.S. Wilson, S.E. Leurgans, P.A. Boyle, and D.A. Bennett Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment Archives of Neurology 68 2011 351 356
18. H. Amieva, G.M. Le, X. Millet, J.M. Orgogozo, K. Peres, and P. Barberger-Gateau Prodromal Alzheimer's disease: successive emergence of the clinical symptoms Ann Neurol 64 2008 492 498
19. E. Grober, C.B. Hall, R.B. Lipton, A.B. Zonderman, S.M. Resnick, and C. Kawas Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease J Int Neuropsychol Soc 14 2008 266 278
20. B.J. Small, and L. Backman Longitudinal trajectories of cognitive change in preclinical Alzheimer's disease: a growth mixture modeling analysis Cortex 43 2007 826 834
21. C.M. Stonnington, K. Chen, W. Lee, D.E. Locke, A.C. Dueck, and X. Liu Fibrillar amyloid correlates of preclinical cognitive decline Alzheimers Dement 10 2014 e1 e8
22. K.E. Pike, K.A. Ellis, V.L. Villemagne, N. Good, G. Chetelat, and D. Ames Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study Neuropsychologia 49 2011 2384 2390
23. K.A. Ellis, Y.Y. Lim, K. Harrington, D. Ames, A.I. Bush, and D. Darby Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta J Alzheimers Dis 34 2013 861 871
24. Y.Y. Lim, P. Maruff, R.H. Pietrzak, D. Ames, K.A. Ellis, and K. Harrington Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease Brain 137 2014 221 231
25. R.A. Sperling, K.A. Johnson, P.M. Doraiswamy, E.M. Reiman, A.S. Fleisher, and M.N. Sabbagh Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiol Aging 34 2013 822 831
26. R.J. Caselli, A.C. Dueck, D. Osborne, M.N. Sabbagh, D.J. Connor, and G.L. Ahern Longitudinal modeling of age-related memory decline and the APOE ε4 effect N Engl J Med 361 2009 255 263
27. P.K. Crane, A. Carle, L.E. Gibbons, P. Insel, R.S. Mackin, and A. Gross Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Brain Imaging Behav 6 2012 502 516
28. L.E. Gibbons, A.C. Carle, R.S. Mackin, D. Harvey, S. Mukherjee, and P. Insel A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment Brain Imaging Behav 6 2012 517 527
29. N.M. Dowling, B. Hermann, R.A. La, and M.A. Sager Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease Neuropsychology 24 2010 742 756
30. K.M. Hayden, M. Kuchibhatla, H.R. Romero, B.L. Plassman, J.R. Burke, and J.N. Browndyke Pre-clinical cognitive phenotypes for Alzheimer disease: a latent profile approach Am J Geriatr Psychiatry 2013 Sep 27
31. S.B. Hendrix Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time Alzheimers Res Ther 4 2012 24
32. C. Xiong, G. van Belle, K. Chen, L. Tian, J. Luo, and F. Gao Combining multiple markers to improve the longitudinal rate of progression: application to clinical trials on the early stage of Alzheimer's disease Stat Biopharm Res 5 2013 54 66
33. S. Balsis, A.A. Unger, J.F. Benge, L. Geraci, and R.S. Doody Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores Alzheimers Dement 8 2012 288 294
34. J. Hobart, S. Cano, H. Posner, O. Selnes, Y. Stern, and R. Thomas Putting the Alzheimer's cognitive test to the test II: Rasch measurement theory Alzheimers Dement 9 1 Suppl 2013 S10 S20
35. W.R. Shankle, A.K. Romney, J. Hara, D. Fortier, M.B. Dick, and J.M. Chen Methods to improve the detection of mild cognitive impairment Proc Natl Acad Sci U S A 102 2005 4919 4924
36. N. Raghavan, M.N. Samtani, M. Farnum, E. Yang, G. Novak, and M. Grundman The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials Alzheimers Dement 9 2013 S21 S31
37. L.L. Barnes, R.C. Shah, N.T. Aggarwal, D.A. Bennett, and J.A. Schneider The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia Curr Alzheimer Res 9 2012 734 745
38. D.A. Bennett, J.A. Schneider, A.S. Buchman, L.L. Barnes, P.A. Boyle, and R.S. Wilson Overview and findings from the Rush Memory and Aging Project Curr Alzheimer Res 9 2012 646 663
39. D.A. Bennett, J.A. Schneider, Z. Arvanitakis, and R.S. Wilson Overview and findings from the religious orders study Curr Alzheimer Res 9 2012 628 645
40. R.S. Wilson, L.A. Beckett, L.L. Barnes, J.A. Schneider, J. Bach, and D.A. Evans Individual differences in rates of change in cognitive abilities of older persons Psychol Aging 17 2002 179 193
41. R.S. Wilson, L.L. Barnes, K.R. Krueger, G. Hoganson, J.L. Bienias, and D.A. Bennett Early and late life cognitive activity and cognitive systems in old age J Int Neuropsychol Soc 11 2005 400 407
42. D.A. Bennett, J.A. Schneider, A.S. Buchman, L.C. Mendes de, J.L. Bienias, and R.S. Wilson The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort Neuroepidemiology 25 2005 163 175
43. D.A. Bennett, R.S. Wilson, J.A. Schneider, D.A. Evans, L.A. Beckett, and N.T. Aggarwal Natural history of mild cognitive impairment in older persons Neurology 59 2002 198 205
44. D.A. Bennett, J.A. Schneider, N.T. Aggarwal, Z. Arvanitakis, R.C. Shah, and J.F. Kelly Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study Neuroepidemiology 27 2006 169 176
45. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
46. L.L. Barnes, J.A. Schneider, P.A. Boyle, J.L. Bienias, and D.A. Bennett Memory complaints are related to Alzheimer disease pathology in older persons Neurology 67 2006 1581 1585
47. J.A. Schneider, Z. Arvanitakis, S.E. Leurgans, and D.A. Bennett The neuropathology of probable Alzheimer disease and mild cognitive impairment Ann Neurol 66 2009 200 208
48. D.A. Bennett, J.A. Schneider, J.L. Bienias, D.A. Evans, and R.S. Wilson Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions Neurology 64 2005 834 841
49. L.K. McEvoy, S.D. Edland, D. Holland, D.J. Hagler Jr., J.C. Roddey, and C. Fennema-Notestine Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease Alzheimer Dis Assoc Disord 24 2010 269 277
50. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, and R.C. Green The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 8 1 Suppl 2012 S1 S68
51. Food and Drug Administration Guidance for industry Alzheimer's disease: developing drugs for the treatment of early stage disease. Draft guidance 2013 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. Accessed March 13, 2014
52. Ayutyanont N, Langbaum JB, Hendrix SB, Chen K, Fleisher AS, Friesenhahn M, et al. The Alzheimer's Prevention Initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. J Clinical Psychiatry. In press.
53. K.P. Riley, G.A. Jicha, D. Davis, E.L. Abner, G.E. Cooper, and N. Stiles Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition J Alzheimers Dis 25 2011 707 717
54. M. Haenlein, and A.M. Kaplan A beginner's guide to partial least squares analysis Understanding Statistics 3 2004 283 297
55. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 280 292